D. Serin

1.6k total citations
73 papers, 1.2k citations indexed

About

D. Serin is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, D. Serin has authored 73 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 46 papers in Oncology, 28 papers in Cancer Research and 19 papers in Pulmonary and Respiratory Medicine. Recurrent topics in D. Serin's work include Cancer Treatment and Pharmacology (29 papers), Breast Cancer Treatment Studies (27 papers) and Advanced Breast Cancer Therapies (9 papers). D. Serin is often cited by papers focused on Cancer Treatment and Pharmacology (29 papers), Breast Cancer Treatment Studies (27 papers) and Advanced Breast Cancer Therapies (9 papers). D. Serin collaborates with scholars based in France, Belgium and United Kingdom. D. Serin's co-authors include P. Fumoleau, M. Namer, R. Largillier, B. Audhuy, Jean‐François Morère, Hubert Orfeuvre, Véronique Dièras, Thierry Lesimple, E. Vuillemin and François Montestruc and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and British Journal of Cancer.

In The Last Decade

D. Serin

67 papers receiving 1.2k citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
D. Serin 759 430 375 203 190 73 1.2k
G G Ribeiro 255 0.3× 309 0.7× 320 0.9× 199 1.0× 176 0.9× 26 850
Marit Holmqvist 329 0.4× 277 0.6× 293 0.8× 112 0.6× 49 0.3× 19 766
James Hackett 946 1.2× 497 1.2× 425 1.1× 52 0.3× 140 0.7× 30 1.4k
Peter C. Willsher 629 0.8× 403 0.9× 390 1.0× 171 0.8× 147 0.8× 48 1.3k
Robert L. DeWitty 462 0.6× 164 0.4× 370 1.0× 136 0.7× 41 0.2× 36 983
H. Hamed 402 0.5× 330 0.8× 383 1.0× 58 0.3× 104 0.5× 36 995
Shulamith Rizel 526 0.7× 329 0.8× 418 1.1× 269 1.3× 26 0.1× 46 1.2k
Keren Sturtz 618 0.8× 285 0.7× 438 1.2× 50 0.2× 44 0.2× 18 971
Francesco Nuzzo 710 0.9× 127 0.3× 351 0.9× 132 0.7× 38 0.2× 48 1.2k
D.F. Easton 354 0.5× 354 0.8× 202 0.5× 80 0.4× 63 0.3× 22 1.2k

Countries citing papers authored by D. Serin

Since Specialization
Citations

This map shows the geographic impact of D. Serin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by D. Serin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites D. Serin more than expected).

Fields of papers citing papers by D. Serin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by D. Serin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by D. Serin. The network helps show where D. Serin may publish in the future.

Co-authorship network of co-authors of D. Serin

This figure shows the co-authorship network connecting the top 25 collaborators of D. Serin. A scholar is included among the top collaborators of D. Serin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with D. Serin. D. Serin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Brain, Étienne, Christelle Lévy, D. Serin, et al.. (2011). High rate of extra-haematological toxicity compromises dose-dense sequential adjuvant chemotherapy for breast cancer. British Journal of Cancer. 105(10). 1480–1486. 6 indexed citations
3.
Cutuli, B., D. Serin, Youlia Kirova, et al.. (2009). Male breast cancer. Evolution of treatment and prognostic factors. Analysis of 489 cases. Critical Reviews in Oncology/Hematology. 73(3). 246–254. 125 indexed citations
4.
Pivot, Xavier, Olivier Rixe, Jean‐François Morère, et al.. (2008). Breast cancer screening in France: results of the EDIFICE survey. International Journal of Medical Sciences. 5(3). 106–112. 8 indexed citations
5.
Kurtz, Jean‐Emmanuel, Frédérique Rousseau, Nicolás Meyer, et al.. (2007). Phase II Trial of Pegylated Liposomal Doxorubicin-Cyclophosphamide Combination as First-Line Chemotherapy in Older Metastatic Breast Cancer Patients. Oncology. 73(3-4). 210–214. 11 indexed citations
6.
Mancini, Julien, Jean Genève, Florence Dalenc, et al.. (2007). Decision-making and breast cancer clinical trialsHow experience challenges attitudes. Contemporary Clinical Trials. 28(6). 684–694. 23 indexed citations
7.
8.
9.
Tolédano, A., P. Garaud, D. Serin, et al.. (2006). La chimiothérapie concomitante de la radiothérapie augmente la toxicité tardive après chirurgie conservatrice du cancer du sein. Cancer/Radiothérapie. 10(4). 158–167. 7 indexed citations
10.
Serin, D., Mark Verrill, Andrew Jones, et al.. (2005). Vinorelbine alternating oral and intravenous plus epirubicin in first-line therapy of metastatic breast cancer: results of a multicentre phase II study. British Journal of Cancer. 92(11). 1989–1996. 10 indexed citations
11.
12.
Fogelman, I., Glen M. Blake, R.W. Blamey, et al.. (2003). Bone mineral density in premenopausal women treated for node-positive early breast cancer with 2 years of goserelin or 6 months of cyclophosphamide, methotrexate and 5-fluorouracil (CMF). Osteoporosis International. 14(12). 1001–1006. 87 indexed citations
13.
Fumoleau, P., R. Largillier, Véronique Dièras, et al.. (2003). Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer. European Journal of Cancer. 40(4). 536–542. 247 indexed citations
14.
Nahon, Stéphane, et al.. (2001). [Axillary lymph node and bone marrow micrometastases of breast cancer].. PubMed. 88(11). 1095–104. 1 indexed citations
15.
Veronesi, Umberto, S. von Kleist, A. Costa, et al.. (1999). Caring about women and cancer (CAWAC). European Journal of Cancer. 35(12). 1667–1675. 41 indexed citations
16.
Thürlimann, Beat, R. Paridaens, D. Serin, et al.. (1997). Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on aminoglutethimide: a phase ii multicentre multinational study. European Journal of Cancer. 33(11). 1767–1773. 119 indexed citations
17.
18.
Julian‐Reynier, Claire, François Eisinger, F Chabal, et al.. (1996). Cancer genetics clinics: Target population and consultees' expectations. European Journal of Cancer. 32(3). 398–403. 32 indexed citations
19.
Williams, C J, V. Barley, G. Blackledge, et al.. (1995). Multicentre cross-over study of aminoglutethimide and trilostane in advanced postmenopausal breast cancer. Clinical Oncology. 7(2). 87–92. 9 indexed citations
20.
Gérard, J.P., Michel Héry, D Gedouin, et al.. (1993). Postmenopausal Patients with Node-Positive Resectable Breast Cancer. Drugs. 45(Supplement 2). 60–67. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by G G Ribeiro Breakdown of academic impact, for papers by Marit Holmqvist Breakdown of academic impact, for papers by James Hackett Breakdown of academic impact, for papers by Peter C. Willsher Breakdown of academic impact, for papers by Robert L. DeWitty Breakdown of academic impact, for papers by H. Hamed Breakdown of academic impact, for papers by Shulamith Rizel Breakdown of academic impact, for papers by Keren Sturtz Breakdown of academic impact, for papers by Francesco Nuzzo Breakdown of academic impact, for papers by D.F. Easton
Rankless by CCL
2026